Gilles Salles

Gilles Salles is a French University Professor, Medical Doctor and a specialist in haematological oncology, notably lymphomas.

Gilles Salle
NationalityFrench
Alma materClaude Bernard University Lyon 1
Scientific career
FieldsHematology Lymphoma
InstitutionsSouth Lyon Hospital Complex, Lyon, France

Salles is the head of the Steering Committee of the CALYM consortium.

Career

He has obtained his master DEA degree in Differentiation, Genetics and Immunology from the Claude Bernard University of Lyon in 1986. In 1989 he continued his university studies and graduated as a Doctor of Medicine, in 1992 he obtained an Advanced Specialised Studies Degree in Cancerology. 1994 he defended his thesis in immunology on the Signals that regulate the formation of B lymphocytes. He has completed his post-doctorate fellowship at the Dana Farber Cancer Institute of the Harvard Medical School of Boston in the United States.[1]

Since 1996, he is the head of the research team “Indolent B-cell proliferation” currently affiliated with the Laboratoire de Biologie Moléculaire de la Cellule (UMR5239 : ENS-Lyon, CNRS, Université Claude Bernard, Hospices Civils de Lyon), that examines several aspects of lymphoma biology (senescence and apoptosis in lymphocytes, biology of splenic marginal zone, prognostic factors in lymphoma). He will leave his duties at the Lyon Sud hospital to take up the duties of head of department in the United States.

Previous he also held the Chair of the Leukaemia Committee of the “Fondation de France” (2005–07) and the Chair of the Scientific Programme Committee of the European Hematology Association (EHA) for its 13th Congress (2008).

At the moment Gilles Salles holds the following positions: - Professor of Medicine (Haematology) at Université Lyon-1, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux (1996) - Chair of the Clinical Haematology Department at the Hospices Civils de Lyon (Centre Hospitalier Lyon-Sud) (2011) - Chair of the research team “Indolent B-cell proliferation” in the LBMC - UMR 5239 (ENS - CNRS – UCB - HCL) (2007) - Chair of the LYSA cooperative group (leading cooperative group in lymphoma research) (2012) - Vice-president in charge of research at the board of Directors of the Hospices Civils de Lyon (2010) - Member of the Editorial Board of Blood (2014) - Head of the Steering Committee of the CALYM consortium

He is also a member of several professional societies, including the American Society of Hematology

Research

Salles has been especially interested in the clinical and biological study of malignant lymphoma – major focuses of his work include the description and validation of prognostic factors as well as clinical trials in indolent lymphomas. He has been involved as a coordinator or co-investigator in many clinical trials and studies within his field. Gilles Salles has led a phase I/II study[2] of rituximab, the antibody that is used most often in the treatment of lymphoma.[3]

Salles is the author of 303 publications.[4]

Video interviews

Recent publications
gollark: The US is like a country, but it's stupid.
gollark: In total, fewer than 5% of people are.
gollark: Not EVERYONE is in the ÜS.
gollark: No.
gollark: Mostly. There also seem to be system monitoring alerts of some kind from what looks like an IT company.

References
  1. "The teams". Fondation Synergie. Retrieved 10 June 2014.
  2. "Obinutuzumab (GA101), a New Generation Rituximab". cornell-lymphoma.com. New Developments in Lymphoma. Retrieved 10 June 2014.
  3. "Rituximab and other antibodies in the treatment of lymphoma" (PDF). lymphomas.org.uk. Lymphoma Association.
  4. "Gilles Salles - PubMed - NCBI". www.ncbi.nlm.nih.gov. Retrieved 7 January 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.